nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.03.2003 | Original Article

Lymph node metastasis of squamous cell carcinoma from an unknown primary: impact of positron emission tomography

verfasst von: Sandro J. Stoeckli, Katarzyna Mosna-Firlejczyk, Gerhard W. Goerres

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2003

Einloggen, um Zugang zu erhalten

Abstract

This study was performed to assess the potential benefit of positron emission tomography (PET) using fluorine-18 fluorodeoxyglucose (FDG) in patients with cervical metastasis of squamous cell carcinoma from an unknown primary tumour. Eighteen patients with cervical metastasis of squamous cell carcinoma from an unknown primary who were assessed by physical examination including transnasal fibre-endoscopy and radiological work-up with computed tomography were included in this prospective tertiary referral centre cohort study. The results of the search for the primary with rigid panendoscopy of the upper aerodigestive tract were compared to the evaluation with FDG PET. Panendoscopy revealed a primary tumour in 8/18 (44%) patients. PET accurately diagnosed five of these eight primary tumours, and gave one false positive and three false negative scans, resulting in a sensitivity of 63%, a specificity of 90%, an accuracy of 78%, a positive predictive value of 83% and a negative predictive value of 75%. Small primaries or primaries in areas with physiologically increased FDG uptake can be missed with PET owing to the limited resolution of the camera (approximately 5 mm). Our study in a small number of patients suggests that PET does not provide benefit in terms of detecting additional primary tumours if applied in addition to extensive clinical work-up. Considering its high specificity, PET could be of value as an initial evaluation instrument, reserving the need for extensive work-up to patients with negative scans.

Schapira DV, Jarrett AR. The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma. Arch Intern Med 1995; 155:2050–2054.

Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med 1993; 329:257–263.

Engzell U, Jacobsson PA, Sigurdson A, Zaijicek J. Aspiration biopsy of metastatic carcinoma in lymph nodes of the neck. Acta Otolaryngol 1971; 72:138–147.

Nordstrom DG, Tewfik HH, Latourette HB. Cervical lymph node metastases from an unknown primary. Radiat Oncol Biol Phys 1979; 5:73–76.

Knothe J, Fritsche F. Zur Halslymphknotenmetastasierung bei unbekanntem Primärtumor. Laryngol Rhinol Otol 1980; 59:221–226.

Leipzig B, Winter ML, Hokanson JA. Cervical node metastases of unknown origin. Laryngoscope 1981; 91:593–598.

Strasnick B, Moore DM, Abermayor E, Juillard G, Fu YS. Occult primary tumors. Arch Otolaryngol Head Neck Surg 1990; 116:173–176.

Wang RC, Goepfert H, Barber AE, Wolf P. Unknown primary squamous cell carcinoma metastatic to the neck. Arch Otolaryngol Head Neck Surg 1990; 116:1388–1393.

Subramanian R, Chilla R. Halslymphknotenmetastasen bei unbekanntem Primärtumor. HNO 1995; 43:299–303.

10.

Martin HE, Morfit HM. Cervical lymph node metastases as the first symptom of cancer. Surg Gynecol Obstet 1944; 78:133–159.

11.

Muir C. Cancer of an unknown primary site. Cancer 1995; 75:353–356.

12.

Abbruzzese JL, Raber MN. Unknown primary. In: Abeloff MF, Armitage JO, Lichter AS, et al., eds. Clinical oncology. New York: Churchill Livingstone; 1995:1833–1845.

13.

Nowak B, Di Martino E, Jaenicke S, Cremerius U, Adam G, Zimny M, Reinartz P, Buell U. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin 1999; 38:312–318.

14.

AAssar OS, Fischbein NJ, Caputo GR, Kaplan MJ, Price DC, Singer MI, Dillon WP, Hawkins RA. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. Radiology 1999; 210:177–181.

15.

Schipper JH, Schrader M, Arweiler D, Muller S, Sciuk J. Positron emission tomography for primary tumor detection in lymph node metastases with unknown primary tumor. HNO 1996; 44:254–257.

16.

Greven KM, Keyes JW Jr, Williams DW 3rd, McGuirt WF, Joyce WT 3rd. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-d-glucose. Cancer 1999; 86:114–118.

17.

Rege S, Maass A, Chaiken L, Hoh CK, Choi Y, Lufkin R, Anzai Y, Juillard G, Maddahi J, Phelps ME. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 1994; 73:3047–3058.

18.

Hanasono MM, Kunda LD, Segall GM, Ku GH, Terris DJ. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope 1999; 109:880–885.

19.

Safa AA, Tran LM, Rege S, Brown CV, Mandelkern MA, Wang MB, Sadeghi A, Juillard G.The role of positron emission tomography in occult primary head and neck cancers. Cancer J Sci Am 1999; 5:214–218.

20.

Bohuslavizki KH, Klutmann S, Sonnemann U, Thoms J, Kroger S, Werner JA, Mester J, Clausen M. F-18 FDG PET zur Detektion des okkulten Primärtumors bei Patienten mit Lymphknotenmetastasen der Halsregion. Laryngorhinootologie 1999; 78:445–449.

21.

Bohuslavizki KH, Klutmann S, Kroger S, Sonnemann U, Buchert R, Werner JA, Mester J, Clausen M. FDG PET detection of unknown primary tumors. J Nucl Med 2000; 41:816–822.

22.

Lassen U, Daugaard G, Eigtved A, Damgaard K, Friberg L.¹⁸F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer 1999; 35:1076–1082.

23.

Braams JW, Pruim J, Kole AC, Nikkels PG, Vaalburg W, Vermey A, Roodenburg JL. Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg 1997; 26:112–115.

24.

Jungehulsing M, Scheidhauer K, Damm M, Pietrzyk U, Eckel H, Schicha H, Stennert E. 2[F]-fluoro-2-deoxy-d-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg 2000; 123:294-301.

25.

Kole AC, Nieweg OE, Pruim J, Hoekstra HJ, Koops HS, Roodenburg JL, Vaalburg W, Vermey A. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998; 82:1160–1166.

26.

Mukherji SK, Drane WE, Mancuso AA, Parsons JT, Mendenhall WM, Stringer S. Occult primary tumors of the head and neck: detection with 2-[F-18] fluoro-2-deoxy-d-glucose SPECT. Radiology 1996; 199:761–766.

27.

Mendenhall WM, Mancuso AA, Parsons JT, Stringer SP, Cassisi NJ. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Head Neck 1998; 20:739–744.

28.

Stokkel MP, Terhaard CH, Hordijk GJ, van Rijk PP. The detection of unknown primary tumors in patients with cervical metastases by dual-head positron emission tomography. Oral Oncol 1999; 35:390–394.

29.

Perie S, Talbot JN, Monceaux G, Grahek D, Kerrou K, Montravers F, St Guily JL. Use of a coincidence gamma camera to detect primary tumor with 18fluoro-2-deoxy-glucose in cervical lymph node metastases from an unknown origin. Ann Otol Rhinol Laryngol 2000; 109:755–760.

30.

Reske SN, Kotzerke J.FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med 2001; 28:1707–1723.

31.

Kostakoglu L, Wong JC, Barrington SF, Cronin BF, Dynes AM, Maisey MN. Speech-related visualization of laryngeal muscles with fluorine-18-FDG. J Nucl Med 1996; 37:1771–1773.

32.

Kamel E, Hany TF, Burger C, Treyer V, Lonn AH, von Schulthess GK, Buck A. CT vs⁶⁸Ge attenuation correction in a combined PET/CT system: evaluation of the effect of lowering the CT tube current. Eur J Nucl Med Mol Imaging 2002; 29:346–350.

33.

Jones AS, Phillips DE, Helliwell TR, Roland NJ. Occult node metastases in head and neck squamous carcinoma. Eur Arch Otorhinolaryngol 1993; 250:446–449.

34.

Minn H, Paul R, Ahonen A, et al. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18-fluorodeoxyglucose. J Nucl Med 1988; 29:1521–1525.

35.

Zimny M, Wildberger JE, Cremerius U, Di Martino E, Jaenicke S, Nowak B, Buell U. Combined image interpretation of computed tomography and hybrid PET in head and neck cancer. Nuklearmedizin 2002; 41:14–21.

Titel: Lymph node metastasis of squamous cell carcinoma from an unknown primary: impact of positron emission tomography
verfasst von: Sandro J. Stoeckli
Katarzyna Mosna-Firlejczyk
Gerhard W. Goerres
Publikationsdatum: 01.03.2003
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2003
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-002-1078-9

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2003

Nuclear medicine technologist training in European countries

Guidelines for 131I-Ethiodised Oil (Lipiodol) Therapy

Uptake of FDG in Lemierre's syndrome with normal leucocyte scintigraphy

125I-BMIPP and 18F-FDG uptake in a transgenic mouse model of stunned myocardium

The Essential Physics of Medical Imaging

MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model